 |
市場調査レポート
商品コード
1448398
膣炎治療薬の世界市場規模、シェア、成長分析：タイプ別、治療法別、流通チャネル別 - 産業予測（2024～2031年）Global Vaginitis Therapeutics Market Size, Share, Growth Analysis, By Type, By Treatment, By Distribution channel - Industry Forecast 2024-2031 |
||||||
| 膣炎治療薬の世界市場規模、シェア、成長分析：タイプ別、治療法別、流通チャネル別 - 産業予測（2024～2031年） |
|
出版日: 2024年03月05日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の膣炎治療薬の市場規模は、2022年に4億4,000万米ドルとなり、予測期間（2024～2031年）のCAGRは25.6%で、2023年の5億5,000万米ドルから、2031年までには34億2,000万米ドルに成長する見通しです。
膣感染症にかかる人が増えているため、膣感染症治療の世界市場は拡大しています。市場は、抗菌薬やプロバイオティクスの使用に重点を置いた、個別化され侵襲性の低い治療へと移行しています。新しい技術は、新しい治療法や感染症を診断するツールの開発に役立っています。市場の大手企業は研究に資金を費やし、より多くの製品を作るために他社と協力しています。北米と欧州は医療制度が整っており、人々が感染症について知っているため、市場の大部分を占めています。しかし、急速に発展しているアジア太平洋諸国では、より多くの人々がヘルスケアを受けられるようになり、これらの感染症について学んでいるため、大きな成長が見込まれます。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
膣炎治療薬の世界市場：タイプ別
- 市場概要
- 細菌性膣炎
- イースト菌感染症
- トリコモナス症
膣炎治療薬の世界市場：治療法別
- 市場概要
- 抗真菌薬・抗生物質の薬
- 局所クリーム
- 家庭療法
膣炎治療薬の世界市場：流通チャネル別
- 市場概要
- 薬局
- eコマース
- 小売店
膣炎治療薬の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Pfizer Inc.（USA）
- Johnson & Johnson（USA）
- Novartis AG（Switzerland）
- GlaxoSmithKline plc（UK）
- Bayer AG（Germany）
- Sanofi（France）
- Merck & Co., Inc.（USA）
- Eli Lilly and Company（USA）
- AstraZeneca plc（UK/Sweden）
- AbbVie Inc.（USA）
- Gilead Sciences, Inc.（USA）
- Roche Holding AG（Switzerland）
- Bristol Myers Squibb（USA）
- Teva Pharmaceutical Industries Ltd.（Israel）
- Astellas Pharma Inc.（Japan）
- Mylan N.V.（USA）
- Daiichi Sankyo Co., Ltd.（Japan）
- Takeda Pharmaceutical Company Limited（Japan）
- Boehringer Ingelheim（Germany）
- Sun Pharmaceutical Industries Ltd.（India）
Global Vaginitis Therapeutics market size was valued at USD 0.44 billion in 2022 and is poised to grow from USD 0.55 billion in 2023 to USD 3.42 billion by 2031, at a CAGR of 25.6% during the forecast period (2024-2031).
The worldwide market for treating vaginal infections is growing because more people are getting these infections. The market is moving towards treatments that are personalized and less invasive, with a focus on using antimicrobial drugs and probiotics. New technology is helping create new treatments and tools for diagnosing infections. Big companies in the market are spending money on research and working with others to make more products. North America and Europe have big parts of the market because they have good healthcare systems and people know about these infections. But countries in Asia-Pacific that are developing quickly could see big growth because more people are getting access to healthcare and learning about these infections.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaginitis Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Vaginitis Therapeutics Market Segmental Analysis
The global vaginitis therapeutics market is segmented on the basis of type, treatment, distribution channel, and region. By Type, the market is segmented into bacterial vaginosis, yeast infection, and trichomoniasis. By Treatment, the market is segmented into antifungal and antibiotic medications, topical creams, and home remedies. By Distribution channel, the market is segmented into pharmacies, e-commerce, and retail stores. By Region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Drivers of the Global Vaginitis Therapeutics Market
Vaginitis, which includes different types of vaginal infections and inflammation, is a common problem for women all over the world. Many women have it, so there's a big need for treatments that work well. Things like not keeping clean, using some types of birth control, taking antibiotics, and changes in hormones can make vaginitis more likely to happen.
Restraints in the Global Vaginitis Therapeutics Market
Antibiotics are often used to treat bacterial vaginosis, a type of vaginitis. But using antibiotics too much or not in the right way has made some bacteria become resistant to them. This means antibiotics might not work as well to treat bacterial vaginosis, and it can be harder to manage the infection.
Market Trends of the Global Vaginitis Therapeutics Market
A big trend in treating vaginal infections is that more women are learning about their reproductive health. They want to know more about how to find out if they have an infection, how to treat it, and how to stop it from happening again. Because of this, more women might see a doctor early on if they think they have an infection, which means there's a bigger need for treatments that work well.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Vaginitis Therapeutics Market by Type
- Market Overview
- Bacterial vaginosis
- yeast infection
- and trichomoniasis
Global Vaginitis Therapeutics Market by Treatment
- Market Overview
- Antifungal and antibiotic medications
- topical creams
- and home remedies
Global Vaginitis Therapeutics Market by Distribution channel
- Market Overview
- Pharmacies
- e-commerce
- and retail stores
Global Vaginitis Therapeutics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (UK/Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Daiichi Sankyo Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
